Scientists find 'total switch' to control malignant breast cancer

In a recent study published in the international journal Lancer Cell, scientists from the Salk Institute identified a special "total switch" that appears to control the dynamic behavior of tumor cells that can make certain types of cancer difficult to cope with.
researcher Geoffrey Wahl said the gene, called Sox10, directly controls the growth and invasion of triple-negative breast cancer, which returns to a flexible early state found in fetal breast tissue, a cell reprogramming that may be new to cancer formation. Cell types, and the key to drug tolerance and transfer to other parts of the body, describe sox10's key role in this process, and the findings may help researchers understand the mechanisms by which cancer occurs, without developing new ways to diagnose and treat malignant breast cancer.
There are two characteristics that make triple-negative breast cancer difficult to deal with, one is heterogeneity, i.e. there are many different cell types in a single tumor, and the other is that breast cancer metastrises, and in a sense, researchers are able to target one type of cell, but there are other types of cells in the tumor that are resistant, similar to chromatin changing color to avoid predators.
In order to develop from a single cell called a complete organism, such as mice or humans, embryos and fetal cells must have the ability to divide rapidly, while also being able to move and transform into many different cell types in the body, a trait known as "plasticity", but the plasticity is often turned off by plastic cells, but for reasons that some researchers don't know, they are likely to wake up again and develop cancerous variants."
researcher Christopher Dravis says embryos can pressurized certain cells to initiate critical developmental processes and produce new tissue, but when the body doesn't need them, the cells are shut down, which is important because in malignant breast cancer, the researchers found that some of the safety mechanisms that regulate these powerful developmental genetic processes are missing, so the processes behind cell plasticity are reactivated to drive tumors to occur, eventually causing the cancer to worsen. In the study, researchers found for the first time which genes may be activated during the development of the body by detecting which parts of the DNA in mouse breast cells are easier to dissomble, and after analyzing chromatin, the researchers said that in fetal cells and breast tumor cell subpopulations, the same area of the genome becomes easier to get close to, in which Sox10 turns on multiple body development processes in the nouritary DNA, which appears to be evidence of genetic regulation.
In fetal cells, the binding points of Sox10 are open and easily accessible compared to healthy formed cells, and the researchers later said Sox10 was actually able to bind to and activate the expression of genes in the open region, directly regulating the cells responsible Types, movements, and other genes associated with the evolution and metastasis of breast cancer cells; breast cancer cells with higher sox10 expression levels can become more primitive and gain the ability to move without Sox10, and without Sox10, no cells in breast cells that can be reprogrammed to transform cancer can form tumors.
researchers point out that strategies to block Sox10 need further research and development, and that safety tests are needed to determine whether it affects normal cellular function, and that Sox10 can actually regulate many genes associated with malignant breast cancer, which may serve as a special target to help researchers develop individualized therapies for metastasis breast cancer, and that the next step is to look further into finding potential drug targets in the genes sox10 regulates, which are funded by NIH and NCI. (Bio Valley)